Prosecution Insights
Last updated: November 04, 2026
Application No. 18/260,056

COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES

Non-Final OA §102§112§DOUBLEPATENT
Filed
Jun 30, 2023
Priority
Dec 31, 2020 — DE 10 2020 135 172.0 +1 more
Examiner
BELL, SARA ELIZABETH
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Heliatek GmbH
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
45 granted / 66 resolved
+8.2% vs TC avg
Strong +40% interview lift
Without
With
+40.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
39 currently pending
Career history
116
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
22.7%
-17.3% vs TC avg
§102
25.1%
-14.9% vs TC avg
§112
32.3%
-7.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 66 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Current Status This action is responsive to the amended claims of 06/30/2023. Claims 1-16 are pending. Claims 8 and 10 are withdrawn. Claims 1-7, 9, and 11-16 have been examined on the merits. Election/Restrictions Applicant’s election of the species of Formula (I) compound 12 in the reply filed on 09/09/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). A search for the elected species compound 12 did not retrieve any prior art (see SEARCH 6 of the attached search notes). Thus, the search was extended to the other species of claim 13 – no prior art for the claimed species was retrieved. Thus, the search was extended to the following species: PNG media_image1.png 141 339 media_image1.png Greyscale . This species retrieved prior art. This species reads on claims 1-7, 9, 11-12, and 14-16. Since claim 13 retrieved no prior art, the claim is examined here. Claims 8 and 10 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/09/2026. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. The effective filing date is 12/30/2021. Information Disclosure Statement The information disclosure statement (IDS) submitted on 09/28/2023 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Specification Applicant is reminded of the proper content of an abstract of the disclosure. In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., “The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics.” Exemplification of a species could be illustrative of members of the class. For processes, the type of reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary. Please amend the instant abstract to recite the general nature of the claimed compound, e.g., dinitrile substituted furan-pyrroles, or an exemplary species. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. Please amend the title to reflect the nature of the compounds claimed, similar to the abstract. Claim Objections Claims 1-7, 9, and 11-16 are objected to because of the following informalities. Appropriate correction is required. Claims 1-2 recite structures for M, N, T1, T2, T3, and T4 and structures for A1 and A2, respectively. Please add the word “and” before the final structure recited for each of these variables. Dependent claims 3-7, 9, and 11-16 are similarly objected to since they do not rectify the issue. Claim 4 recites “a, b, d, e equals 0” in line 2. Please add either “and” or “or” before the “e” in this phrase. Further, the claim recites “parameters a, b equals 1” and “parameters d, e equals 1” in lines 5-6. Please replace the “,” in each phrase with the word “or”. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-7, 9, 11-12, and 14-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection. MPEP 2163(I) states “The written description requirement has several policy objectives. "[T]he ‘essential goal’ of the description of the invention requirement is to clearly convey the information that an applicant [inventor] has invented the subject matter which is claimed." In re Barker, 559 F.2d 588, 592 n.4, 194 USPQ 470, 473 n.4 (CCPA 1977). Another objective is to convey to the public what the applicant claims as the invention. See Regents of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1566, 43 USPQ2d 1398, 1404 (Fed. Cir. 1997), cert. denied, 523 U.S. 1089 (1998). "The ‘written description’ requirement implements the principle that a patent must describe the technology that is sought to be patented; the requirement serves both to satisfy the inventor’s obligation to disclose the technologic knowledge upon which the patent is based, and to demonstrate that the patentee [inventor] was in possession of the invention that is claimed." Capon v. Eshhar, 418 F.3d 1349, 1357, 76 USPQ2d 1078, 1084 (Fed. Cir. 2005).” Factors considered in making the determination as to whether the artisan would recognize that the applicant was in possession of the claimed invention as a whole at the time of filing include: (a) Actual reduction to practice; (b) Disclosure of drawings or structural chemical formulas; (c) Sufficient relevant identifying characteristics such as: (i) Complete structure, (ii) Partial structure, (iii) Physical and/or chemical properties or (iv) Functional characteristics when coupled with a known or disclosed correlation between function and structure; (d) Method of making the claimed invention; (e) Level of skill and knowledge in the art and (f) Predictability in the art. The Instant Disclosure: Claim 1 is drawn to a compound of a very broad genus Formula (I) PNG media_image2.png 35 336 media_image2.png Greyscale wherein Z is present 1-3 times and comprises two components groups M and N each chosen from a set of 4 formulas comprising 2-6 variables; A1 and A2 are chosen from the very broad group of any electron withdrawing group as long as it contains a C=C bond; T1-T4 are chosen from a set of 8 formulas and of T1-T4 at least one has to be present (a, b, d, or e = 1) while the others are either absent or present (a, b, d, or e = 0 or 1). The only uniting structural limitations on the structure of Formula (I) are: 1) at least one of T1-T4 must be formula (10) (comprising 3 further variables) and 2) a nitrogen of group M and an oxygen of group N are linked by 2 carbon atoms. However, the genus of Formula (I) comprises at least thousands of species due to this vast variability in each of A1, A2, T1-T4, and Z. Claims 15-16 are drawn to a device comprising the compound of Formula (I) as broadly defined in claim 1. This lack of structural definition does not allow the artisan to envisage the compounds which are part of the invention (see Factors (b) and (c) above). Claims 2-7, 9, 11-12, and 14 attempt to narrow the scope of Formula (I); however, each claim depends directly from claim 1 and only limits a small portion of the structure to a smaller pool of variability. For example, claim 14 recites wherein “c = 1, b = 1, and/or e = 1.” This does not define any concrete chemical structural elements in Formula (I) as each of the affected variables Z, T2, and T4 are still chosen from the full scope of formulas disclosed in claim 1. Similarly, while claim 2 defines 3 formulas from which A1 and A2 are chosen, the formulas still comprise many degrees of variability and the rest of the compound is left as broadly defined in claim 1. Claim 13 and the specification (Pg. 18 Table 1) only disclose 18 species of Formula (I) – these species do not cover the breadth of the claimed genera. The 18 species comprise M is Formula (1) or (3), N is Formula (4), A1 & A2 are Formula (7), and all T1-T4 are Formula (10) or (11). Compound (31) lies outside of Formula (I) and discloses M as Formula (7). Each of these formulas in claim 1 have multiple points of variability; however, the claimed species only support as small portion of that variability. A1 and A2 are always PNG media_image3.png 54 65 media_image3.png Greyscale ; Formula (10) is PNG media_image4.png 46 42 media_image4.png Greyscale , PNG media_image5.png 46 42 media_image5.png Greyscale , PNG media_image6.png 68 55 media_image6.png Greyscale , or PNG media_image7.png 64 61 media_image7.png Greyscale ; Formula (11) is always CH=CH; M is always a pyrrole or indole; and N is a PNG media_image5.png 46 42 media_image5.png Greyscale and once is a PNG media_image6.png 68 55 media_image6.png Greyscale . Further, the specification only provides synthetic schemes for 3 of the 18 species (Pg. 28-32). This disclosure does not meet Factors (a)-(d) for the full scope of the rejected claims. MPEP 2163(II)(A)(2) states “The disclosure of an element may be critical where those of ordinary skill in the art would require it to understand that inventor was in possession of the invention… Amgen, Inc. v. Chugai Pharm.Co., Ltd., 927 F.2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991) ("it is well established in our law that conception of a chemical compound requires that the inventor be able to define it so as to distinguish it from other materials, and to describe how to obtain it").” After review of the specification and claims, Applicant has not defined the compound of Formula (I) in a way that distinguishes it from other materials (e.g., see the prior art applied below) and Applicants have not described how to obtain the full scope of Formula (I). Thus, it has not been demonstrated that the Applicant was in possession of the invention that is claimed. Level of Skill and Knowledge in the Art: The relative skill of those in the art is high, generally that of a Ph.D. The artisan using Applicant’s invention would generally be a synthetic or physical chemist with several years of professional experience. However, it is noted that each embodiment of the invention is required to be individually assessed to determine which compounds exhibit the desired photovoltaic properties. AZZOUZI (Azzouzi, M. et al., Digital Discovery, 2025, 4, 2781-2796) discloses the identification of organic molecules with desirable properties from the extensive chemical space can be challenging, particularly when property evaluation methods are time consuming and resource-intensive (Pg. 2781 Abstract). This challenge is illustrated by exploring the chemical space of oligomers (6-mer) for potential use in organic photovoltaics (Pg. 2781 Abstract). While AZZOUZI discloses an algorithm that performs better than random search in large chemical spaces (Pg. 2781 Abstract), they disclose that testing the search algorithm in a benchmark dataset, however close the benchmark is to the task at hand, does not translate to a net improvement when deployed on a larger chemical space (Pg. 2794 Left ¶3). This discrepancy stems from the benchmark dataset’s fundamental unbalanced representation of the broader chemical space (Pg. 2794 Left ¶3). This “fundamental unbalanced representation of the broader chemical space” is analogous to the instant case wherein the 18 disclosed species of Formula (I) cannot provide an unbiased representation of the full scope of the broader chemical space encompassed by Formula (I). Thus, the predictability of further species within Formula (I) which would have similar or even better photovoltaic properties is low, even when advanced search algorithms are utilized. Note, this is especially true since AZZOUZI is published years after the instant effective filing date (EFD). If something is unpredictable after the EFD, it must be unpredictable before/at the EFD. Thus, Factors (e) and (f) are not met. Conclusions: Due to the breadth of Formula (I) as defined by claims 1-7, 9, 11-12, and 14-16, the lack of direction given in the claims/specification regarding embodiments of Formula (I) which show the desired activity, and the challenges in the art, the artisan would not be able to immediately envisage the full breadth of Formula (I). General methods of making compounds are known to the artisan, however the instant disclosure does not inform the artisan of what combination of elements are necessary for the instant compounds to possess the disclosed photovoltaic activity. Accordingly, the specification fails to provide adequate written description for the genus of the claims and does not reasonably convey to the artisan that the inventor(s), at the time the application was filed, had possession of the entire scope of the claimed invention. Thus, claims 1-7, 9, 11-12, and 14-16 are rejected as lacking written description for the full scope of compound of Formula (I). The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7, 9, and 11-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites structures for variables M, N, T1, T2, T3, and T4. All structures are of very low resolution making the variables and atoms unreadable. For example, PNG media_image8.png 107 163 media_image8.png Greyscale PNG media_image9.png 102 173 media_image9.png Greyscale it is impossible to be sure of the nature of the variables: e.g., X?, O or Q. Further, since the structures are unclear, it is impossible to verify the variables recited throughout the claim. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Dependent claims 2-7, 9, and 11-16 are similarly rejected since they do not rectify the issue. To overcome: please provide higher resolution images of all claim 1 structures. Claim 1 recites for variables R, R1 to R3, R5, R6, and R9 multiple instances of “cyclic or open-chain C1-C10 alkyl”. It is impossible to have a cyclic C1-C2 alkyl. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Dependent claims 2-7, 9, and 11-16 are similarly rejected since they do not rectify the issue. Claim 1 recites: for R “H, halogen, branched or linear, cyclic or open-chain C1-C10 alkyl, C2-C10 alkenyl”, for R1 to R3 “H, branched or linear, cyclic or open-chain C1-C10 alkyl, substituted or unsubstituted C2-C10 alkenyl”, for R5 and R6 “C2-C10 alkenyl, alkynyl, branched or linear, cyclic or open-chain C1-C10 alkyl”, and for R9 “H, CN, branched or linear, cyclic or open-chain C1-C10 alkyl, C2-C10 alkenyl”. The use of commas to separate the chemical moieties makes unclear the delineation between each moiety. Does the “branched or linear” stand on its own – if so what is this moiety? Do the phrases “branched or linear” and “cyclic or open-chain” only apply to the C1-C10 alkyl or do they apply to multiple of the recited moieties (e.g., also C2-C10 alkenyl)? Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Dependent claims 2-7, 9, and 11-16 are similarly rejected since they do not rectify the issue. To overcome: consider using semicolons alongside commas to separate the moieties, e.g., “H; halogen; branched or linear, cyclic or open-chain C1-C10 alkyl; C2-C10 alkenyl” wherein semicolons separate distinct moieties/groups of related moieties. Claim 1 recites in lines 5-6 of variable R “ PNG media_image10.png 50 578 media_image10.png Greyscale ”. It is unclear what H atoms can be substituted with – any other atom or only moieties chosen from CN or NR10R11. It is also unclear how CN or NR10R11 relate to the rest of the paragraph – are they further R groups or are they substituents on R? Thus, the overall scope of R is unclear and the metes and bounds of the claim are undefined rendering the claim indefinite. Dependent claims 2-7, 9, and 11-16 are similarly rejected since they do not rectify the issue. Claim 1 recites variable R13 on Pg. 6. R13 is not defined and is not found in any of the structures recited within the claim. It is unclear what R13 is and how it interacts with R5 and R6 as suggested on Pg. 6. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Dependent claims 2-7, 9, and 11-16 are similarly rejected since they do not rectify the issue. Claim 2 recites “formula 7” and “formula 8”. These formulas are already recited in parent claim 1 for structures under groups M and N. The structures in claim 1 differ from those shown in claim 2. Thus, it is unclear if the structures in claim 2 are inadvertently different from the same labeled structures in claim 1 or if they should be different. The shared names “formula 7” and “formula 8” create uncertainty in the claimed structures. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. To overcome: please rename the formulas 7 and 8 in claim 2 to numbers which are not already utilized. Please make sure this change is carried through to any other claims reciting such formulas. Claim 2 recites variables R4, R12, R13, R7, and R8 in formulas 7 and 8. These variables are not defined in the claim. Variables R4, R12, R13, R7, and R8 are defined in the claim; however, since these variables have the number as a subscript it cannot be assumed that these are the same variables as R4, R12, R13, R7, and R8. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Claim 2 recites for variable R13, R7, and R8 “alkynyl, branched or linear, cyclic or open-chain C1-C10alkyl”. First, it is impossible to have a cyclic C1-C2 alkyl (see ¶21). Second, the use of commas to separate the moieties and descriptors for such moieties makes the delineation between the moieties unclear (same logic as ¶22). Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Claim 2 recites PNG media_image11.png 187 586 media_image11.png Greyscale . The phrase “in which” implies that the variables V, Y, and U apply to the R13 and R5/R6 ring closure discussed just prior. However, no formula for such ring closure is provided, so it is unclear how V, Y, and U relate to the ring closure. Variables V, Y, and U are seen in formulas 8-9, recited earlier in claim 2; however, the phrasing “in which” appears to apply these variables only to R13 and R5/R6 ring closure. Thus, it is unclear how and where to apply variables V, Y, and U. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Claim 3 recites PNG media_image12.png 85 90 media_image12.png Greyscale . First, variables R4 and R12 are not defined, only variables R4 and R12 are defined in the text (logic of ¶26). Second, no R13 is defined in the text of claim 3 or parent claim 1. Thus, the structure recited above is unclear. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Note, the structure still properly further limits parent claim 1 since the only limitation on A1/A2 in claim 1 is a C=C bond that is clearly found in the above structure. Claim 6 recites PNG media_image13.png 28 254 media_image13.png Greyscale as Formula (II), a subgenus of Formula (I) claim 1. However, claim 1 Formula (I) utilizes subscripted a, b, d, and e on the T variables: PNG media_image14.png 21 242 media_image14.png Greyscale . Due to this discrepancy, it is unclear if the a, b, d, and e of claim 2 are the same as those recited in claim 1. An alternate reading could be that a, b, d, and e of claim 2 are some newly introduced moieties which have not been properly defined. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Claim 7 recites for R “H, halogen, branched or linear, and cyclic or open-chain C1-C10 alkyl”. Similar to ¶21, a cyclic C1-C2 alkyl is impossible. Similar to ¶22, the use of commas to delineate moieties is unclear. Further, the use of “and” before “cyclic or open-chain further separates “branched or linear” from the C1-C10 alkyl. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Claim 7 recites “R5 and R6”. There is a lack of antecedent basis for these limitations in the claims. No structure in either of claim 7 or parent claim 1 comprises an R5 or R6. Claim 1 recites R5 and R6, but due to the difference in subscripted number these cannot be assumed to be the same variables. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Claim 12 lacks a period (struck by last amendment). It is unclear if the claim is complete. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Claim 13 recites compound 31: PNG media_image15.png 96 416 media_image15.png Greyscale . There is a lack of antecedent basis for this limitation in the claims. Parent claim 1 requires “wherein M and N are each linked such that at least one N atom of the group M and an O atom of the group N are each bonded to one another via 2 C atoms”. The M group of compound 31 is the indole comprising the NH (dashed arrow). The N group may be either of the attached furan groups; however, to comply with claim 1 the O of the furan can only be 2 C away from the NH of M. In either case, the O is 3 C (dashed arrow) or 5 C (solid arrow) away. Thus, compound 31 is outside of the scope of Formula (I) as defined by parent claim 1. The metes and bounds of the claim are undefined rendering the claim indefinite. Claim 1 recites “wherein M and N are each linked” on Pg. 5. It is unclear if the “N” recited here is group N of Z (i.e., M-N, N-M) or if it is a nitrogen (N). At each other instance of group N of Z the phrase “group(s) N” is used making it clear what N refers to. However, in the above instance, the identity of N is unclear. Thus, the metes and bounds of the claim are undefined rendering the claim indefinite. Dependent claims 2-7, 9, and 11-16 are similarly rejected since they do not rectify the issue. To overcome: please consistently utilize “group(s) N” throughout the claim(s) when referring to the group N of Z. Withdrawn claim 10 also suffers from this issue. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 6-7 and 13 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 6 recites PNG media_image13.png 28 254 media_image13.png Greyscale which does not fall within the scope of Formula (I) as defined by claim 1, see explanation ¶30. Thus, claim 6 does not properly further limit the parent claim 1. Claim 7 recites “R5 and R6” of the compound of claim 1. These variables are not found in the compound of claim 1 (see ¶32). Thus, claim 7 does not properly further limit the parent claim 1. Claim 13 recites compound 31 (see ¶34) which falls outside of the scope of Formula (I) of parent claim 1 by virtue of the M-N linkage. Thus, claim 13 does not properly further limit the parent claim 1. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-7, 9, 11-12, and 14-16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by MATTERSTEIG (WO 2018/220148). A machine translation of MATTERSTEIG is cited below for text portions. The original document is cited for images/structures. Both documents are provided attached. Regarding claims 1-7, 9, 11-12, and 14, MATTERSTEIG teaches a compound of instant Formula (I): PNG media_image1.png 141 339 media_image1.png Greyscale (original doc. Pg. 40 Fig. 10 DCV-Fu-Py-Fu-V-Me). This compound can be interpreted under instant Formula (I) in 3 ways. In each case: c is 1; M is Formula (1) wherein R1 is C1 alkyl, X1 and X2 are C-R wherein R is H; N is Formula (4) wherein X9 and X10 are C-R wherein R is H; and A1 and A2 are each electron-withdrawing groups comprising a C=C of Formula (7) wherein R4 and R12 are CN and R13 is H. The nitrogen of the M group is linked to the oxygen of the N group via 2 carbon atoms. Further, at least one of T1-T4 is Formula (10) in each interpretation. In case 1) PNG media_image16.png 371 563 media_image16.png Greyscale , the furan-CH=CH moiety is either T2-T1 wherein a and b are each 1 (d and e are 0) or T3-T4 wherein d and e are each 1 (a and b are 0). The furan corresponds to formula (10) wherein A is O and X17-X18 are C-R wherein R is H. The CH=CH moiety corresponds to formula (11) wherein R5 and R6 are H. Z is linked as T1-T2-M-N or as N-M-T3-T4. There are two possible compounds: A1-T1-T2-M-N-A2 or A1-N-M-T3-T4-A2. In case 2) PNG media_image17.png 364 570 media_image17.png Greyscale , the left-most furan is T1 or T2 of formula (10) and the CH=CH moiety is T3 or T4 of formula (11). Formulas (10) and (11) are interpreted as explained in case 1). There are four possible combinations: a=1, b=0, d=1, & e=0; a=1, b=0, d=0, & e=1; a=0, b=1, d=1, & e=0; or a=0, b=1, d=0, & e=1. Z is linked as (T1/T2)-M-N-(T3/T4). In case 3) PNG media_image18.png 364 570 media_image18.png Greyscale , the left-most furan is T3 or T4 of formula (10) and the CH=CH moiety is T1 or T2 of formula (11). Formulas (10) and (11) are interpreted as explained in case 1). There are four possible combinations: a=1, b=0, d=1, & e=0; a=1, b=0, d=0, & e=1; a=0, b=1, d=1, & e=0; or a=0, b=1, d=0, & e=1. Z is linked as (T1/T2)-N-M-(T3/T4). Regarding claims 15-16, MATTERSTEIG teaches an organic optoelectronic device comprising two electrodes and at least one photoactive layer between them (Pg. 1 claim 1 – translation); i.e., an electrode and a counter-electrode. MATTERSTEIG teaches an exemplary device having the compound above as the photoactive layer (Pg. 70 ¶260 – translation). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-6, 11-12, and 14-16 are provisionally rejected on the ground of anticipatory nonstatutory double patenting as being unpatentable over claims 1, 8, and 10 of copending Application No. 18/724,198 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. Reference claim 8 is drawn to compounds A25, A26, A38, A40, A41, and A42, each of which fall under instant Formula (I). These species anticipate the instant claims. For each species: c is 1 and A1 and A2 are PNG media_image19.png 54 64 media_image19.png Greyscale . For A25 PNG media_image20.png 123 307 media_image20.png Greyscale : M is Formula (1), N is Formula (5), and T1/T2/T3/T4 is furan Formula (10); the furan may be any one of T1, T2, T3, or T4 wherein the corresponding a, b, d, or e is 1 and the others are 0. For A26 PNG media_image21.png 124 307 media_image21.png Greyscale : M is Formula (1), N is Formula (5), and T1/T2/T3/T4 is thiophene Formula (10); the thiophene may be any one of T1, T2, T3, or T4 wherein the corresponding a, b, d, or e is 1 and the others are 0. For A38 PNG media_image22.png 112 369 media_image22.png Greyscale : M is Formula (1), N is Formula (5), T2/T3 is furan Formula (10), T1/T4 is thiazole Formula (10); the Ts may be present as T2-T1 (a, b = 1; d, e = 0) or T3-T4 (a, b = 0; d, e = 1). For A40 PNG media_image23.png 128 336 media_image23.png Greyscale : M is Formula (1), N is Formula (5), and T1/T2/T3/T4 is furan Formula (10); the furan may be any one of T1, T2, T3, or T4 wherein the corresponding a, b, d, or e is 1 and the others are 0. For A41 PNG media_image24.png 138 334 media_image24.png Greyscale : M is Formula (1), N is Formula (5), and T1/T2/T3/T4 is furan Formula (10); the furan may be any one of T1, T2, T3, or T4 wherein the corresponding a, b, d, or e is 1 and the others are 0. For A42 PNG media_image25.png 104 416 media_image25.png Greyscale : M is Formula (3), N is Formula (5), and T1/T2/T3/T4 is furan Formula (10); the furan may be any one of T1, T2, T3, or T4 wherein the corresponding a, b, d, or e is 1 and the others are 0. Reference claim 1, from which ref. claim 8 depends, is drawn to the genus Formula encompassing these species. Reference claim 10 is drawn to an organic electronic device comprising an electrode, counter electrode, and at least one organic photoactive layer between the electrodes comprising at least one compound of ref. claim 1. Together with the species of ref. claim 8, the ref. claims 1 and 10 also anticipate the instant claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Claims 1-7, 9, and 11-16 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARA ELIZABETH BELL whose telephone number is (703)756-5372. The examiner can normally be reached Monday-Friday 9:00-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /S.E.B./Examiner, Art Unit 1625 /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Jun 30, 2023
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780819
COMPOUNDS AND METHODS OF USE
4y 2m to grant Granted Nov 03, 2026
Patent 12760015
CRYSTAL OF PDE3/PDE4 DUAL INHIBITOR AND USE THEREOF
4y 3m to grant Granted Oct 13, 2026
Patent 12728113
MICROSUSPENSION OF AN MDM2 INHIBITOR AND THERAPEAUTIC APPLICATIONS THEREOF
3y 9m to grant Granted Sep 08, 2026
Patent 12702660
A METHOD FOR TREATING CANCER WITH AN ORAL DOSAGE FORM OF AN ESTROGEN RECEPTOR-ALPHA INHIBITOR
4y 8m to grant Granted Aug 11, 2026
Patent 12697335
METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS
3y 6m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+40.0%)
3y 8m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 66 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month